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Mitochondria are critical modulators of cell function and are increasingly recognized as
proximal sensors and effectors that ultimately determine the balance between cell survival
and cell death. Volatile anesthetics (VA) are long known for their cardioprotective effects, as
demonstrated by improved mitochondrial and cellular functions, and by reduced necrotic
and apoptotic cell death during cardiac ischemia and reperfusion (IR) injury. The molecular
mechanisms by which VA impart cardioprotection are still poorly understood. Because of
the emerging role of mitochondria as therapeutic targets in diseases, including ischemic
heart disease, it is important to know if VA-induced cytoprotective mechanisms are
mediated at the mitochondrial level. In recent years, considerable evidence points to
direct effects of VA on mitochondrial channel/transporter protein functions and electron
transport chain (ETC) complexes as potential targets in mediating cardioprotection. This
review furnishes an integrated overview of targets that VA impart on mitochondrial
channels/transporters and ETC proteins that could provide a basis for cation regulation and
homeostasis, mitochondrial bioenergetics, and reactive oxygen species (ROS) emission in
redox signaling for cardiac cell protection during IR injury.
Keywords: volatile anesthetics, isoflurane, mitochondrial bioenergetics, electron transport chain, cardiac IR injury,
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INTRODUCTION
In recent years the mitochondrion has gained recognition as
a key factor in the etiology of numerous diseases (Duchen,
2004), including cardiac ischemia and reperfusion (IR) injury
(Ferrari, 1996; Murphy and Steenbergen, 2008b). Mitochondria
Abbreviations: VA, volatile anesthetics; IR, ischemia and reperfusion; ETC, elec-
tron transport chain; ROS, reactive oxygen species; m, mitochondrial mem-
brane potential; MI, myocardial ischemia; CAD, coronary artery disease; OxPhos,
oxidative phosphorylation; IPC, ischemic pre-conditioning; PKB, protein kinase B;
PKC, protein kinase C; PKA, protein kinase A; ERK, extracellular regulated kinases;
APC, anesthetic-preconditioning; RISK, reperfusion injury salvage kinase; CaMK,
calcium/calmodulin-dependent protein kinases; GSK, glycogen synthase kinase;
RNS, reactive nitrogen species; mKATP, mitochondrial ATP sensitive K+-channel;
mBKCa, mitochondrial big Ca2+ sensitive K+ channel; mPTP, kilodalton (kDa),
mitochondrial permeability transition pore; mNCE, mitochondrial Na+-Ca2+
exchanger; OMM, outer mitochondrial membrane; IMM, inner mitochondrial
membrane; VDAC, voltage-dependent anion channel; PTMs, post-translational
modifications; ATP, adenosine triphosphate; IP3, inositol triphosphate receptor;
ANT, adenosine nucleotide transport; TCA, tricarboxylic acid; ADP, adenosine
triphosphate; NHE, sodium hydrogen exchanger; NCE, sodium calcium exchanger;
5-HD, 5-hydroxydecanoic acid; mCU, mitochondrial calcium uniporter; CyP-
D, cyclophilin D; PPIase, peptidylprolyl cis-trans isomerase; CSA cyclosporin A;
eNOS, endothelial nitric oxide synthase; APoC, anesthetic-post-conditioning; GPR,
G protein coupled receptor; HSP, heat shock protein; ALDH2, aldehyde dehy-
drogenase 2; 4-HNE, 4-Hydroxynonenal; Q·, ubisemiquinone; UCPs, uncoupling
proteins; NF-κB, nuclear factor–κB; O-GlcNAc, O-linked-β-N-acetylglucosamine;
miRNA, micro RNA; mDNA, mitochondrial DNA.
act as critical triggers, mediators, and effectors in protective
strategies directed against IR injury and other pathological sit-
uations (Camara et al., 2010, 2011). Cardioprotective strategies
include a complex cascade of signaling events (Zaugg and Schaub,
2003) that not only involve the electron transport chain (ETC)
but also key factors in the intrinsic anti-apoptotic signaling path-
ways that lead to cell protection. Consequently, mitochondria
have emerged as regulators of the redox signaling, which is cru-
cial in determining cell fate, i.e., life or death (Brookes et al.,
2004).
Cardiac IR-induced mitochondrial dysfunction is accompa-
nied by reduced membrane potential (m), decreased adeno-
sine triphosphate (ATP) production, impaired Ca2+ homeostasis,
increased “bad” reactive oxygen species (ROS) emission, matrix
swelling and membrane permeability, and release of cytochrome
c and other apoptotic factors leading to cell death (Steenbergen
et al., 1990; Stowe and Camara, 2009) (Figure 1). Pre- and post-
conditioning by volatile anesthetics (VA) have emerged as useful
strategies to protect the myocardium against IR injury (Zaugg
et al., 2003b; Pagel, 2008; Hu and Liu, 2009; Camara et al., 2010).
Indeed, the guidelines of the American College of Cardiology and
the American Heart Association recommend the maintenance
of VA for non-cardiac surgery in patients with increased risk
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FIGURE 1 | Targets of mitochondria and sequence of changes in cytosolic
and mitochondrial function during cardiac ischemia and reperfusion (IR)
injury. During ischemia (A) reduced O2 promotes anaerobic glycolysis that
generates increased cytosolic lactate (lacc) leading to acidification. Increased
H+ activates Na+-H+ exchanger (NHE) leading to increase cytosolic Na+
([Na+]c), which activates Na+-Ca2+ exchanger (NCE), causing an increase in
cytosolic Ca2+ ([Ca2+]c) which in turn increases mitochondrial matrix Ca2+
([Ca2+]m). Impaired electron transport leads to increased generation of
reactive oxygen species (ROS) beginning with superoxide (O·−2 ); impaired
respiration and substrate utilization leads to uncoupling with lowered
mitochondrial membrane potential (m) and decreased generation of
mitochondrial ATP. During reperfusion (B), the increase in deleterious ROS
damages major macromolecules including tricarboxlic acid (TCA) enzymes,
membrane transporters, electron transport chain (ETC) proteins and
mitochondrial DNA (mtDNA). Also during reperfusion, m is restored and
[Ca2+]m and ROS further increase to produce even greater mitochondria
damage that induces mitochondrial permeability transition pore (mPTP)
opening and release of cytochrome c (cyt C) that in turn triggers apoptosis.
Other abbreviations: OMM, outer mitochondrial membrane; IMM, inter
mitochondrial membrane; IMS, inter mitochondrial space.
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of myocardial ischemia (Fleisher et al., 2007). VA directly target
many proteins to modulate their activities, which necessarily
complicates analysis of their beneficial effects due to vague struc-
tural and dynamic consequences of VA interactions with their
target proteins (Eckenhoff and Johansson, 1997). Also, despite
advances noted in this review, the complete mitochondrial tar-
gets and mechanisms responsible for the protection afforded by
VA remain unclear.
This review focuses primarily on the protein targets and func-
tional effects of VA in mediating myocardial protection against
IR injury. A special emphasis is given to the direct effects of
VA on selected mitochondrial proteins and their implicated
mitochondrial mechanisms for myocardial protection against
IR injury. There are several cardioprotective strategies or treat-
ments against IR injury directed to mitochondria (Krolikowski
et al., 2005; Mewton et al., 2010; Chakrabarti et al., 2013; Jones
et al., 2013). Indeed, the cardioprotective effects of VA, which
likely include mitochondrial effects, have been tested clinically
(Belhomme et al., 1999; Julier et al., 2003; Van der Linden et al.,
2003; Zaugg et al., 2003a).
Bridging the gap between bench and bedside should be
strengthened by unique therapeutic approaches against IR injury
that are targeted to mitochondria. Indeed, because VA as a class
are very lipophilic, unlike most other protective drugs, they
readily penetrate mitochondria to target the more lipophilic
protein sites embedded in the membrane structure. Thus
by examining the role of lipophilic agents in mitochondrial-
mediated cardioprotection, we may be able to define a new
paradigm for mitochondrial protection that could lead to novel
approaches to protect the heart in the clinical situation. We hope
the information summarized here will provide helpful insights
into the potential of synergistic effects of VA at multiple sites in
mitochondria that underlie their cardioprotective effects.
MOLECULAR BINDING SITES FOR VA
X-ray crystallography, molecular modeling, and structure–
function studies indicate that anesthetics bind in hydrophobic
cavities formed within proteins (Bertaccini et al., 2007). The
lipophilic (or hydrophobic) nature of these binding sites underlies
the Meyer–Overton correlation between anesthetic lipophilicity
and potency (Hemmings, 2010). VA exhibit amphiphilicity (pos-
sessing both weak polar and nonpolar characteristics), which is
required for effective interaction with these hydrophobic cav-
ities, as indicated by a better Meyer–Overton correlation with
more polar solvents (Hemmings, 2010). However, identification
of anesthetic binding sites on any given target protein is quite dif-
ficult due to the low affinity interactions of VA and the paucity
of atomic resolution structures for pharmacologically relevant
target proteins like membrane bound proteins that are difficult
to resolve structurally. In studies using albumin and luciferase, in
which 3D atomic resolution structures are available, Bertaccini
et al. (2007) found that VA bind in pockets with both nonpo-
lar and polar non-covalent interactions. Binding involves weak
hydrogen bond interactions with polar amino acid residues and
water molecules, nonpolar van der Waals interactions, and a
polarizing effect of the amphiphilic-binding cavity on the rela-
tively hydrophobic anesthetic molecules (Hemmings, 2010).
Internal cavities underlie the conformational flexibility
involved in ion channel gating and ligand-induced signal trans-
duction of receptor proteins. Occupation of a critical volume
within these cavities by VA provides a plausible mechanism for
altering receptor and ion channel function by selective stabiliza-
tion of a particular confirmation, e.g., an open or inactivated
state of an ion channel. VA also acquire binding energy from the
entropy generated by displacing bound water from these relatively
promiscuous binding sites (Hemmings, 2010). Studies of glycine,
GABAA, and NMDA receptors provide convincing evidence for
the existence of anesthetic binding sites in critical neuronal sig-
naling proteins by identifying the amino acid residues critical for
anesthetic action (Wick et al., 1998; Koltchine et al., 1999; Jenkins
et al., 2001; Hemmings, 2010). Although this review centers pri-
marily on VA effects on cardiac mitochondrial protein activities
that confer cardiac protection, it is expected that the molecular
mechanism for VA action at mitochondrial sites are similar to
those for other organelles.
VA AS PHARMACOLOGICAL CONDITIONING AGENTS IN IR
INJURY
Clinically, myocardial ischemia (MI) is characterized by a reduced
oxygen supply to demand ratio in the hearts of patients at
high-risk of coronary artery disease (CAD) or who are under-
going high-risk cardiac surgery. Due to limited blood supply in
the manifestation of MI, IR injury leads to a dysfunctional redox
imbalance inmitochondria with a concomitant decrease in oxida-
tive phosphorylation (OxPhos) and an overall switch to anaerobic
metabolism. Experimental and clinical data have provided several
types of mechanical and pharmacological conditioning strategies
that lead to reduce IR-induced myocardial dysfunction and cell
death as discussed next.
Murry et al. (1986) were the first to coin the concept of
ischemic pre-conditioning (IPC), which involves adaptation of
the myocardium to longer (damaging) IR stress when preceded
by short episodes of repetitive ischemia and reperfusion. IPC
evokes many downstream signaling factors (memory) to provide
a lasting protection from subsequent lethal index ischemia. Many
of the signaling kinases, including Akt/protein kinase B (PKB),
protein kinase C-ε (PKC-ε), and extracellular regulated kinases
(ERK1/2), translocate to mitochondria to contribute to the acute
memory phase in cytoprotection against the impending index
ischemia that can lead to heart damage (Zaugg and Schaub, 2003).
Administration of a VA before myocardial IR as a protective strat-
egy has been described in different animal and human models
(Penta de Peppo et al., 1999; De Hert et al., 2002) as anesthetic-
preconditioning (APC) (Tanaka et al., 2004a). APC invokes
a memory phase by signaling kinases similar to IPC (Zaugg
et al., 2003b). However, the detailed upstream mechanisms of
mitochondrial-mediated protection by VA remain unclear.
Clinically, IPC can be mimicked pharmacologically by a vari-
ety of substances like aspirin, beta-blockers, alpha 2-adrenoceptor
agonists, statins, opioids, and VA (isoflurane, halothane, desflu-
rane, sevoflurane). Myocardial protection by the VA enflurane
was first demonstrated by Freedman et al. (1985) in the iso-
lated rat heart, global ischemia model. Later, Warltier et al.
(1988) reported that halothane and isoflurane enhanced recovery
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of stunned myocardium in dogs during reperfusion. Novalija
and Stowe (1998) reported that APC with sevoflurane mimicked
IPC by improving vascular, mechanical, and metabolic function
in isolated hearts through a sequence of molecular events that
ultimately led to protection.
APC has two phases: an acute phase where the initial trig-
ger phase of protection lasts for a few hours, and a delayed
phase in which the protection is manifested days after washout
of the VA. Although both acute and delayed APC are medi-
tated through complex signal transduction cascades (Weber and
Schlack, 2008), acute APC involves phosphorylation and translo-
cation of preexisting proteins, while delayed APC involves de
novo protein synthesis (Tonkovic-Capin et al., 2002; Tanaka et al.,
2004b; Chiari et al., 2005b). APC shares major signaling events
with IPC (Zaugg and Schaub, 2003; Zaugg et al., 2003b). That is,
like IPC, APC enhances myocardial protection against infarction
during early reperfusion by redox activation of protein kinases
such as PI3K/Akt (as a part of the reperfusion injury salvage
kinase (RISK) pathway), Pim-1 kinase [a member of the family
of calcium/calmodulin-dependent protein kinases (CaMK II)],
ERK1/2, and by glycogen synthase kinase (GSK-3β) dependent
mechanism (Chiari et al., 2005a; Krolikowski et al., 2005, 2006;
Weihrauch et al., 2005; Pagel et al., 2006; Stumpner et al., 2012b).
THE MITOCHONDRION AS A TARGET FOR VA PROTECTION
IN IR INJURY
Mitochondria serve as the targets and end-effectors for a number
of cellular metabolic processes including cell-signaling cascades,
redox control, ion homeostasis, cell growth and cell death. In
cardiomyocytes they are responsible for generating almost 95%
of the cellular ATP; they are also responsible for the majority of
the pathological ROS and reactive nitrogen species (RNS) pro-
duced during IR. VA likely interfere with mitochondrial function
by directly or indirectly targetingmany, but not all, mitochondrial
proteins. Specifically, VA probably directly modulate the function
of known targeted proteins that are believed to underlie themech-
anism of IPC-induced protection against IR injury. Therefore,
APC is of practical importance because administration of a VA
could reduce mortality during ischemic heart surgery, and could
also safely be given to patients who are at high risk, e.g., during
heart transplant procedure (Ramakrishna et al., 2014). Although
the mechanisms for this protection by APC are not well known,
it is now evident that the mitochondrion is a key component in
the beneficial effects of VA administration (Jovic et al., 2012; Mio
et al., 2014).
Based on its pharmacological effects, Kersten et al. (1996)
reported that isoflurane-mediated protection against myocardial
infarction in dogs involved the putative mitochondrial ATP
sensitive K+-channel (mKATP), discussed in detail later. VA
appear to indirectly relax coronary arteries by altering intra-
cellular Ca2+ regulation in the vascular smooth muscle cell by
stimulating mKATP channel opening (Kersten et al., 1996) and/or
opening of the mitochondrial big Ca2+ sensitive K+ channel
(mBKCa) (Redel et al., 2008). To date, potential VA-mediated
cardioprotective mechanisms targeted to mitochondria involve
inhibition of mitochondrial permeability transition pore (mPTP)
opening (Pravdic et al., 2010; Sedlic et al., 2010b) (Figure 2) via
activation of signaling kinases, like PKC (Novalija et al., 2003;
Pravdic et al., 2009), mitochondrial uncoupling (Ljubkovic et al.,
2007; Sedlic et al., 2009; Pravdic et al., 2012), “small” ROS emis-
sion (Tanaka et al., 2002; Novalija et al., 2003; Hirata et al.,
2011), inhibition of mitochondrial Na+-Ca2+ exchange (mNCE)
(Agarwal et al., 2012), modulation of mitochondrial bioener-
getics (Sedlic et al., 2010a; Bienengraeber et al., 2013; Agarwal
et al., 2014) (Figure 2), and opening of mKATP (Kersten et al.,
1996, 1997; Pain et al., 2000; Stadnicka et al., 2006) and mBKCa
channels (Ozcan et al., 2002; Stumpner et al., 2012a). These dif-
fuse effects of VA on mitochondria may be attributed in part to
the complex interactions of the mitochondrial proteins and their
association with the membranes that separates the organelle from
the cytoplasm and in part to the pleiotropic effects of VA on cell
constituents. All of the activators may have a common final path-
way, e.g., the triggering of a “small” amount of ROS to stimulate
downstream protective pathways.
EFFECTS OF VA ON OUTER MITOCHONDRIAL MEMBRANE
PROTEINS
The outer mitochondrial membrane (OMM) contains several
enzymes including monomine oxidase and the integral transport
proteins, porins, which makes the OMM permeable to small
molecules less than 6 kilodaltons (kDa). The voltage-dependent
anion channel (VDAC) constitutes the major porin of the OMM
and it regulates the metabolic and energetic fluxes across the
OMM by transporting metabolites and ions necessary for elec-
tron transfer, bioenergetics, and redox potentials for normal
mitochondrial function. Mammalian mitochondria have three
different VDAC isoforms: 1, 2, and 3 (Craigen and Graham,
2008) that perform different functions (Neumann et al., 2010).
Recent reports also suggest a complex regulation of VDAC by
mechanisms involving protein-protein interactions and post-
translational modifications (PTMs) in normal and pathological
conditions (Shimizu et al., 1999; Liu et al., 2009; Das et al., 2012;
Porter et al., 2012; Yang et al., 2012). Effects of IR or other oxida-
tive stresses can be exhibited by their ultimate actions on VDAC
function. For example, De Stefani et al. (2012) postulated a mech-
anism by which VDAC permeability promotes apoptosis based on
the close anatomic link between VDAC and the inositol triphos-
phate receptor (IP3) that transfers a large amount of Ca2+ from
SR to mitochondria during cytosolic Ca2+ dysregulation.
The clinical relevance of VDAC in inducing apoptosis
(Shoshan-Barmatz and Ben-Hail, 2012) indicates VDAC as a
potential target for therapeutic drugs (Shimizu et al., 2001).
The increased permeability of VDAC by VDAC oligomerization
to create a large pore (Zalk et al., 2005) allows the release of
apoptotic factors (e.g., cytochrome c), which activate proteolytic
enzymes, e.g., the caspases. VDAC normally exists in the open
configuration (Hodge and Colombini, 1997), whereas VDAC clo-
sure is associated with an increase in oxidative stress and increased
Ca2+ dependent mPTP transition (Tikunov et al., 2010). The
channel gating of VDAC from open to partial closure increased
the Ca2+ permeability of VDAC (Rostovtseva et al., 2005) so Ca2+
imbalance may have a permissive role in mediating the mPTP
transition. In contrast, drugs that prevent or impede VDAC
closure could have potential therapeutic utility (Vander Heiden
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FIGURE 2 | A proposed view of cardioprotection by effects of volatile
anesthetics (VA) on electron transport chain (ETC) proteins and on
ADP/ATP transport via voltage-dependent anion channel (VDAC). By
direct attenuation of NADH dehydrogenase (complex I) and cytochrome
bc1 (complex III), VA promote a slightly more reduced redox state and
a slowing of the rates of respiration and phosphorylation. Lowered ATP
entry into the matrix through VDAC/ANT may contribute to reduced
ATPase activity. These events may help to decrease ATP hydrolysis and
so to better maintain cell ATP levels during reperfusion. Preserved ATP
synthesis at complex V would diminish the need for glycolysis while
decreasing lactic acidosis and cytosolic Ca2+ [Ca2+]c (see details in
Figure 1 legend). Other abbreviations: ROS, reactive oxygen species;
mPTP, mitochondrial permeability transition pore; Symbol represents
reverse functioning of NHE and NCE.
et al., 2000; Lemasters and Holmuhamedov, 2006). The modu-
lation of VDAC permeability and release of cytochrome c is also
regulated by other proteins, such as the Bcl-X protein family, the
Bcl-2 homologous antigen/killer (Bak) and Bcl-2 associated X
protein (Bax) (Shimizu et al., 1999); however, their definitive roles
in pore size modulation is still debatable (Vander Heiden et al.,
2000; Shimizu et al., 2001). The downregulation of Bcl-2 and
upregulation of Bax protein in myocytes represents the molecu-
lar triggers and modulators of apoptotic cell death on reperfusion
after ischemia (Zhao et al., 2000).
The anti-apoptotic protein Bcl-2 is also targeted to the
mitochondrion and affects different mitochondrial metabolic
functions (Imahashi et al., 2004). Isoflurane preconditioning was
reported to block the myocardial IR induced decrease in the
expression of anti-apoptotic Bcl-2 protein as well as the expres-
sion of the pro-apoptotic Bax protein; this led to an increase in
the Bcl-2/Bax ratio, mediated through activation of PI3K/Akt sig-
naling (Raphael et al., 2006). VA preconditioning was found to
attenuate myocardial cell apoptosis in rabbits after regional IR via
Akt signaling and modulation of Bcl-2 family proteins (Raphael
et al., 2006). Overexpression of Bcl-2 reduced ischemic injury in
hearts by affecting mitochondrial metabolic function as shown
by a reduced rate of decline in ATP and enhanced acidification,
consistent with Bcl-2 induced inhibition of consumption of
glycolytically generated ATP (Imahashi et al., 2004). These
effects could have been mediated by reduced entry of ATP into
mitochondria via VDAC and/or adenosine nucleotide transport
(ANT), or by direct inhibition of F1F0 ATPase. (Jamnicki-Abegg
et al., 2005) (Figure 2) suggested that isoflurane reduces hypoxia-
induced apoptosis through activation of Akt and by increased
expression of anti-apoptotic Bcl-2 proteins. Thus, accumulat-
ing evidence points to a complex regulation of VDAC per-
meability/gating involving regulation by homo-oligomerization
of VDAC, or by hetero-oligomerization with other mitochon-
drial proteins (e.g., ANT) and extra-mitochondrial proteins (Bak,
Bax). Consequently, there are several potential targets for VA to
exert their effects in the OMM that may reduce lethal permeabi-
lization of VDAC and provide cardioprotection.
Evidence of VDAC regulation by GSK, the serine/threonine
kinase family of proteins involved in glycogen metabolism, pro-
vides for an additional role of VDAC in cell injury during IR.
Phosphorylation at Ser9 led to inhibition of GSK-3β during pre-
conditioning and this was found to be cardioprotective against IR
injury (Nishihara et al., 2006; Gross et al., 2008). The improve-
ment in recovery of perfused rat hearts with a GSK-inhibitor was
attributed to decreased ATP translocation through VDAC/ANT,
or due to reduced ATP hydrolysis by F1F0-ATPase (Das et al.,
2008); either pathway is consistent with decreased utilization of
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ATP as reported by Murry et al. (1986). The same mechanism
of action was proposed to explain the noted improvement in
post-ischemic recovery of mice hearts with overexpressed Bcl-
2 (Chen et al., 2001). This was supported by another study
that showed increased association of VDAC and Bcl-2 during
ischemia (Imahashi et al., 2004). Further, the above mechanisms
of GSK-dependent fall in ATP translocation into mitochondria
was bolstered by a proteomic study that reported alterations in
the expressions of ETC proteins during IPC using a GSK inhibitor
(Wong et al., 2010) so it is interesting that isoflurane. Isoflurane-
induced cardioprotection was also associated with increased levels
of phosphorylation of GSK-3β (Zhu et al., 2010).
EFFECTS OF VA ON INNER MITOCHONDRIAL MEMBRANE
PROTEINS
The inner mitochondrial membrane (IMM) is impermeable to
charged substances and so distinct channels, exchangers, and
pumps are utilized to transport ions and metabolites to and from
the matrix. The IMM also contains the ETC complexes that carry
out OxPhos. This bioenergetic process is dependent on an intri-
cate interplay among the supply of substrates, breakdown and
elimination of metabolites, and ion fluxes across the IMM. For
example, Ca2+ transport into and out of mitochondria is impor-
tant for buffering excess cytosolic Ca2+ and for regulating mito-
chondrial respiration and ATP production to meet the cellular
energetic demands, as in excitation-contraction coupling. Clearly,
the mechanisms underlying myocardial contractile dysfunction
during and after ischemic insults are due in part to impaired
mitochondrial metabolism and ion homeostasis (Bosnjak and
Kampine, 1986; Gerstenblith, 2004). A summary of IMMproteins
that are affected by VA exposure and their implication in cardio-
protection is given in Figure 3. VA-induced effects on respiratory
complexes are discussed under “Mitochondrial bioenergetics as a
target for VA.”
VA AND MITOCHONDRIAL Ca2+ CHANNELS/TRANSPORTERS IN IR
INJURY
Myocardial IR leads to an increase in cytosolic [Ca2+], and con-
sequently to mitochondrial Ca2+ loading (Steenbergen et al.,
1987), which is a major contributor to mitochondria-mediated
necrotic/apoptotic cell injury during IR. APC, like IPC, reduces
cytoplasmic Ca2+ load and improves myocardial Ca2+ respon-
siveness so that reperfusion injury is attenuated (An et al.,
2001). A detailed mechanistic understanding of this process
remains to be explored. However, Riess et al. (2002b) reported
that APC-mediated cardiac protection against Ca2+ overload
on reperfusion was blocked by a putative mKATP inhibitor (5-
hydroxydecanoic acid; 5-HD), suggesting that mKATP channel
opening was associated with a decrease in matrix Ca2+ overload
possibly via attenuated Ca2+ uptake.
FIGURE 3 | A proposed view of cardioprotection by effects of volatile
anesthetics (VA) on mitochondrial Ca2+ overload. VA could mediate
cardioprotection by mildly inhibiting mitochondrial NCE to increase [Ca2+]m
which triggers protective mechanisms before IR injury. Lowered ATP or
higher Ca2+ -induced stimulation of mitochondrial K+ channels may lead to
mild uncoupling by the K+-H+ exchanger (KHE) that may reduce m and
[Ca2+]m during IR via the mitochondrial Ca2+ uniporter (CU) and/or the
putative mitochondrial ryanodine receptor (mRyR). Lowered [Ca2+]m would
decrease “deleterious” ROS emission, impede mPTP opening, and reduce
apoptotic/necrotic cell death on reperfusion. mPTP opening could also be
prevented by a VA-mediated decrease in activation of glycogen synthase
kinase (GSK-3β) via phosphorylation of GSK-3β. Effects of VA on
channels/exchangers suggest potential implications for low Ca2+ and ROS in
the triggering phase of VA cardioprotection.
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The uptake of Ca2+ by the mitochondrial calcium uniporter
(mCU) specifically depends on a large m gradient (Saotome
et al., 2005). Therefore, slight m depolarization represents a
strategy for cardioprotection. In a recent study we (Agarwal et al.,
2012) found that direct exposure of mitochondria to isoflurane at
a physiological Ca2+ concentration (∼200 nM free) led to a Na+-
dependent, but m-independent, increase in mitochondrial
Ca2+ by attenuating NCE without affecting uptake via the mCU.
Moreover, this was consistent with the lack of increase in matrix
Ca2+ in the absence of buffer Na+ so that NCE could not be acti-
vated (Agarwal et al., 2012). These observations are compatible
with a study by Sedlic et al. (2010b), in which a small increase
in Ca2+ uptake was found in mitochondria isolated from isoflu-
rane preconditioned rat hearts, even though mild loss of m
occurred. The decrease in m also attenuated deleterious ROS
production and attenuated mPTP opening. However, despite a
fall in m and a decrease in ROS emission, isolated mitochon-
dria can still exhibit a small rise in matrix Ca2+, so there are
exceptions to the idea that a rise in matrix Ca2+ is only a con-
sequence of ROS-induced Ca2+ release phenomenon (Zima and
Blatter, 2006). In our study (Agarwal et al., 2012), we specu-
lated that the small increase in matrix Ca2+ induced by isoflurane
could be part of the trigger mechanisms that include ROS in
the signaling cascades that underlie VA cardioprotection. This
notion remains to be verified experimentally. If proven, it could
provide a novel insight into the triggering role of matrix Ca2+
in APC.
VA AND MITOCHONDRIAL KATP (mKATP) CHANNELS IN IR INJURY
mKATP channels are thought to be located in the IMM, and like
other mK+ channels with different ligands, are widely recog-
nized as redox sensors of ischemia (e.g., low ATP, high Ca2+, low
pH) that trigger effectors of several survival signaling pathways
involved in pre- and post-conditioning (Gross and Fryer, 1999).
In spite of numerous electrophysiological and pharmacological
approaches to discern the molecular identity and composition
of the mKATP channel, the true identity remains contentious.
Using elaborate experimental approaches involving unbiased
proteomic and pharmacological techniques, the KCNJ1 (ROMK)
was identified in the IMM and demonstrated that ROMK chan-
nels can localize to mitochondria (Foster et al., 2012). The chan-
nel was shown to mediate ATP-sensitive K+ flux and to confer
cytoprotection. However, as noted by Wojtovich et al. (2010)
the assignment of ROMK as the mKATP conflicts with pharma-
cological data on the sensitivity of either channel to ATP and
fluoxetine.
Nonetheless, mKATP channel opening, or any other mK+
channel, may be an important component of mitochondrial and
cellular protection against cardiac IR injury. The cause-effect rela-
tionships of the components that lead to protection, however,
are unclear. APC was reported to cause production of a small
amount of ROS/RNS (Kevin et al., 2005), which could activate
certain intracellular signals, like NO·, that led to activation of
the mKATP channel (Novalija et al., 1999). Putative mKATP chan-
nel openers led to mild swelling and uncoupling of mitochondria
(mild loss of m), and a “small” transient rise in ROS emis-
sion (signaling ROS) associated with a decrease in mitochondrial
Ca2+ load (Wang et al., 2001; Facundo et al., 2006a,b). VA exert
cardioprotective effects that most certainly involve mitochondrial
bioenergetics (discussed later), and also mKATP channel (or other
K+ channels) opening, as reviewed by our group previously (Riess
et al., 2004b; Stowe and Kevin, 2004; De Hert et al., 2005; Kevin
et al., 2005).
Several other reports support the association of VA and KATP
channels on mitochondrial function. Jiang et al. (2007) recon-
stituted fragments of the IMM from human left ventricle, and
based on use of the putative mKATP channel antagonist, 5-HD,
they reported that isoflurane increased the open probability of
the putative mKATP channel. Similarly, H2O2 was able to acti-
vate the putative mKATP channel; this finding was supported by
a similar study (Queliconi et al., 2011). These data confirm that
isoflurane, as well as ROS, directly modulate reconstituted car-
diac mKATP channels without apparent involvement of cytosolic
protein kinases, as commonly proposed. Sevoflurane precondi-
tioning protected the myocardium against IR injury by reducing
mitochondrial Ca2+ loading, again presumably via mKATP chan-
nel opening (Wang et al., 2001; Chen et al., 2002; Liu et al.,
2005). Sevoflurane induced cardioprotection was also proposed
to increase mitochondrial volume via mKATP channel opening
on the basis of effects of putative agonists and antagonists on
KATP channels (Riess et al., 2008b). Desflurane prevented mPTP
opening and this effect was abrogated by pretreatment with a
mKATP channel antagonist, which suggested a link betweenmPTP
opening and mKATP channel activation during cardioprotection
(Riess et al., 2002b, 2003, 2008a; Piriou et al., 2004). However,
the mechanism regulating mKATP dependent mPTP transitions
still remains to be verified. Moreover, the sensitivity and selectiv-
ity of 5-HD and diazoxide as modulators of mKATP channels have
been questioned (Hanley et al., 2002; Lim et al., 2002; O’Rourke,
2004). Thus, although these studies suggest overall that VA act
on mKATP channels as a mechanism to contribute to cell protec-
tion, the effects could have been on other mK+ channels or due
to other upstream mechanisms.
VA AND MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mPTP)
IN IR INJURY
The mPTP is a non-specific channel that allows water, ions,
and solutes with low molecular weights (≤1.5 kDa) to traverse
mitochondrial membranes and enhance ROS emission, mito-
chondrial swelling and cell death. The molecular identity of
the mPTP remains unclear. The mitochondrial matrix protein,
cyclophilin D (CyP-D), a member of a family of highly homol-
ogous peptidylprolyl cis-trans isomerase (PPIase), is believed to
constitute an integral component of the mPTP, and thus to play
an important role in regulating the pore (Nicolli et al., 1996).
Previously it was suggested that the VDAC-ANT-CyP-D com-
plex constituted the structural and functional component of the
mPTP by its sensitivity to cyclosporin A (CsA), an inhibitor of
the pore (Crompton et al., 1998). However, subsequent genetic
loss- and gain-of-functional studies have questioned the rele-
vance of VDAC in the formation of mPTP (Javadov et al., 2009;
Bernardi, 2013). Interestingly, in a recent study, the F1F0-ATP
synthase was proposed to be the mPTP, or at least a compo-
nent of the mPTP complex (Giorgio et al., 2013). Increased
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mitochondrial ROS, in addition to Ca2+ overload, alkalosis, and
ATP depletion (Halestrap, 2010), are major hallmarks of IR
injury and are some of the primary factors that lead to mPTP
opening.
IR-activated pathways of cell death are likely mediated by
mPTP because CsA and sanglifehrin A, inhibitors of the pore,
were found to reduce infarct size (Clarke et al., 2002). Thus,
preventing mPTP opening serves as a clinically relevant thera-
peutic target for treating IR injury. VA-induced cardioprotection
is associated with reduced mPTP opening (Krolikowski et al.,
2005; Pravdic et al., 2009; Sedlic et al., 2010b). NO· produced
by endothelial NO· synthase (eNOS) during cardioprotection
by anesthetic post-conditioning (APoC) was suggested to pre-
vent mPTP opening (Ge et al., 2010). Sevoflurane, like CsA,
increased the threshold of Ca2+-induced mPTP opening when
mediated via GSK-3β inactivation (Onishi et al., 2012). Moreover,
the interaction of PKC-ε and the putative constituents of the
pore (VDAC, ANT) suggested that a signaling mechanism could
modulate mPTP function (Baines et al., 2003). Isoflurane pre-
conditioning reduced cytochrome c release (Qian et al., 2005),
possibly by activating a PKC-3-dependent mechanism linked to
retarded mPTP opening. Isoflurane was found to induce phos-
phorylation of GSK-3β, which was associated with mitochon-
drial protection and reduced IR injury due to attenuated mPTP
opening (Juhaszova et al., 2004). Moreover, phosphorylation of
GSK-3β was reported to increase binding of ANT with phospho-
rylated GSK-3β (Nishihara et al., 2007), which decreased binding
of ANT with CyP-D and suppressed mPTP formation to ulti-
mately confer cardioprotection (Hausenloy et al., 2002; Javadov
et al., 2003). Future confirmation of the molecular identity of
mPTP is indispensable to understanding VA-mediated mecha-
nisms that would potentially retard mPTP opening and confer
cardioprotection. An isoflurane-mediated decrease in ROS pro-
duction inhibited earlier opening of themPTP and reduced apop-
tosis (Wu et al., 2014) during hypoxia/reoxgenation in isolated
cardiomyocytes.
MITOCHONDRIAL BIOENERGETICS AS A TARGET FOR VA
FUNCTION OF MITOCHONDRIAL ELECTRON TRANSPORT CHAIN (ETC)
COMPLEXES
Mitochondria regulate metabolism in addition to synthesizing
ATP. Mitochondrial dysfunction underlies various pathological
processes, including IR injury, as emphasized in this review.
Consequently, preservation of mitochondrial function is neces-
sary to abrogate mitochondrial energy imbalances and apoptotic
signaling pathways that occur in IR injury (Chen et al., 2007).
Delineating the underlying molecular mechanisms that act either
as triggers, activators, or end-effectors is crucial for understand-
ing the complex cardiac protective vs. detrimental mechanisms
mediated by mitochondria. An understanding of how VA alter
mitochondrial bioenergetics is highly significant because mito-
chondrial respiratory dysfunction is reportedly a trigger of IR
injury and VA are cardioprotective. The scheme representing
known VA targets of ETC proteins and their modulating effects
on ETC functions are summarized in Figure 4.
VA are well known to mediate myocardial protection in part
by attenuating the activity of ETC proteins, the first of which
is complex I (Riess et al., 2002a, 2005). Attenuating activity of
complex I appears to produce a small transient increase in ROS,
which could then serve as a trigger for cellular protection (Kevin
et al., 2003; Riess et al., 2004a). During oxidation of complex I
substrate, complex III is considered the principal source for ROS
generation in isolated mitochondria; but this can be inhibited by
limiting electron flow from complex I to complex III (Chen et al.,
2003; Aldakkak et al., 2008). A sevoflurane-mediated decrease in
complex I activity was reversed with ROS scavengers; this sug-
gested that the trigger in protection involves modulation of ETC
complexes and generation of ROS (Riess et al., 2004a).
In our most recent study (Agarwal et al., 2014) we explored
the potential ETC protein targets of isoflurane by comparing its
effects with known ETC inhibitors. We found a differential mod-
ulation of NADH, m, and respiration by isoflurane under
different substrates conditions. We furnished inferential evidence
that isoflurane directly attenuates forward and reverse electron
flow, in a substrate dependent manner, by selectively inhibit-
ing ETC complexes I and III. Complexes II, IV, and V, as well
as ANT activities were unaffected by isoflurane. These results
supported some selectivity of isoflurane in its interaction with
different mitochondrial proteins. With the complex I substrate,
pyruvate/malate, isoflurane decreased the magnitude of state 3
NADH oxidation, increased transient state 3 depolarization, and
depressed state 3 respiration by attenuating complex I in amanner
similar to low concentrations (nM) of a complex I inhibitor
(rotenone).
Limiting complex I activity during ischemia has the potential
to minimize ROS accumulation on reperfusion and so to pro-
tect mitochondria and cells from oxidative damage (Aldakkak
et al., 2008). With the complex II substrate succinate, isoflu-
rane only slightly reduced NADH oxidation,m depolarization
and state 3 respiration (Agarwal et al., 2014). In the presence of
succinate and inhibition of complex I with rotenone, isoflurane
increased the rates of state 3 and 4 respiration by attenuating
complex III activity. Attenuated electron transfer at complex III
leads to electron leak and ROS generation. Thus, the cardiopro-
tective effect of VA against IR injury could be triggered by a small
rise in ROS, which can occur with modulation of the activity
of ETC complexes. This is supported by a study (Ludwig et al.,
2004a), in which an isoflurane-induced small increase in ROS
and reduction in myocardial infarct size in vivo were attenuated
by a complex III inhibitor, but not by a complex I inhibitor. This
study suggested that ROS generation from complex III at some
point during IR injury is a crucial intracellular redox mediator of
isoflurane-induced preconditioning.
The generation of a “small” transient signaling ROS from the
ETC most likely originates from the ubisemiquinone (Q·) radical
intermediate via electron transport in complex III (Chen et al.,
2003) and so this may be a crucial mediator of VA-induced con-
ditioning (Kevin et al., 2003; Ludwig et al., 2004a). Hirata et al.
(2011) reported that isoflurane increased the generation of sig-
naling ROS at complexes I and III, and decreased the reverse
electron flow -mediated detrimental ROS generation, by attenu-
ating complex I activity during reperfusion. Thus, attenuation of
mitochondrial complexes I and III by VA may trigger the signal-
ing ROS that, via downstream pathways, decrease production of
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FIGURE 4 | A proposed view of cardioprotection based on the
modulating effects of volatile anesthetics (VA) on electron transport
chain (ETC) function in the presence of different substrates. Mitochondria
generate reducing equivalents, NADH2 and FADH2, via the tricarboxylic acid
(TCA) cycle in the matrix during electron transfer through the ETC complexes
of the inner mitochondrial membrane (IMM) to generate the proton gradient
(H+) and mitochondrial membrane potential (m). The transfer of electrons
through the ETC complexes to the final electron acceptor, O2, is coupled with
the H+ gradient to phosphorylate ADP to ATP by ATP synthase (complex V).
During electron transfer, attenuation of complex I and complex III generates
O2 free radical anions (O·−2 ) leading to other ROS. Complex II mediates
forward and reverse electron transfer (FET and RET, respectively), which
generates ROS at complex I and complex III. VA modulate complex I and III,
therefore affecting bioenergetics (m, redox state, respiration,
phosphorylation). During oxidation of complex II substrate succinate (Suc),
ROS generated via RET may be considered “deleterious,” while ROS
generated via FET by complex III inhibition may represent the “signaling”
ROS. VA-induced complex I inhibition may decrease the generation of RET
mediated “deleterious” ROS and could mediate the generation of
“signaling” ROS at complex III. Whereas, during oxidation of complex I
substrate pyruvate/malate (PM), VA-induced complex I inhibition could
mediate generation of “signaling” ROS at complex I. VA-induced complex I
and complex III inhibition may mediate slower rates of proton and electron
transfer to reduce ATP synthesis during ischemia to preserve it during
reperfusion. Possible modulating effects of VA on uncoupling protein (UCP) in
promoting proton leak and uncoupling in cardioprotection are also noted.
Other abbreviations: ANT, adenine nucleotide translocase; TCA cycle,
tricarboxylic acid cycle; IMS, inter mitochondrial space.
deleterious ROS from these complexes and confer cardioprotec-
tion. In the isolated heart model, APC alsomay be triggered by the
formation of a small transient amount of RNS, because decreased
cardioprotection was found during VA exposure with application
of either a ROS scavenger or a NO· inhibitor (Novalija et al.,
2002). VA also enhanced myocardial recovery during reperfusion
by opposing the adverse effects of deleterious ROS on cardiac
function (Tanguay et al., 1991). It is also possible that aside from
the direct modulatory effects of VA on ETC complexes that leads
to slight increase in the “triggering” ROS production, VA could
mediate their effects on ROS generation through modulation
of the ROS balance, i.e., generation vs. scavenging, by affecting
the mitochondrial antioxidant defense mechanism (Nickel et al.,
2014).
VA AND MITOCHONDRIAL MEMBRANE POTENTIAL
The active pumping of protons (H+) from thematrix to the inter-
membrane space generates the m necessary for OxPhos. A
H+ leak (uncoupling) in the IMM has potential implications in
both IR injury and in preconditioning (Nadtochiy et al., 2006).
Murphy et al. (2003) suggested that exposure to ROS mediates
activation of uncoupling proteins (UCPs), which tend to reduce
m and hasten respiration. A lowered mitochondrial pH and
m may be markers of VA-induced cardioprotection (Pravdic
et al., 2010). The direct effect of isoflurane to decrease m
due to reduced complex I activity and increased mitochondrial
acidification via an ATP synthase-mediated increase in proton
influx (Pravdic et al., 2012) is another alternative mechanism
for VA-induced cardioprotection. Preconditioning may increase
ROS production due to flavoprotein oxidation andmitochondrial
uncoupling while the decrease inm may be coupled to mKATP
channel opening (Ljubkovic et al., 2007; Sedlic et al., 2009).
Sedlic et al. (2010a) examined isoflurane’s site of action in the
ETC using an isolated rat cardiomyocyte model and reported an
uncoupling-induced depression of m and complex I inhibi-
tion by isoflurane as two potential mechanisms contributing to
protection against IR injury. It was reported that UCP-3 protected
the heart against IR injury and that UPC-3 knockout mice lost the
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cardioprotection conferred by IPC (Ozcan et al., 2013). However,
Pravdic et al. (2012) reported that isoflurane, like UCPs, caused a
mild depolarization and matrix acidification possibly by reducing
complex I function and increasing H+ flux through ATP syn-
thase; they also reported that UCPs appeared not to be involved
in APC. A decrease in m and reduced mitochondrial Ca2+
uptake, with concomitant tolerance to hypoxia-reoxygenation,
was reported to occur in isolated cardiomyocytes and mitochon-
dria examined after cardiac preconditioning in rats (Ljubkovic
et al., 2007). In another study, an APC-induced decrease inm
was reported to be beneficial in decreasing excess ROS emission
and mitochondrial Ca2+ accumulation in oxidatively stressed
cardiomyocytes; this effect was suggested to be due to a mild
uncoupling effect (Sedlic et al., 2010b). However, in many of
these studies the physiological relevance of mild uncoupling by
VA, if it occurred, is questionable (Shabalina and Nedergaard,
2011) because the depression of m was observed only in
isolated mitochondria metabolizing a high concentration of suc-
cinate (Shabalina and Nedergaard, 2011) and exhibiting a large
increase in respiration (Agarwal et al., 2014). Moreover, it is pos-
sible that the mild uncoupling was mediated by an effect of VA to
activate other mK+ channels. In any case, the molecular basis of
VA interactions with the mitochondrial ETC proteins that leads
to decreased or unchangedm is remains unclear.
Oxidative phosphorylation is central to substrate metabolism
and energy production. Wide variations in OxPhos rates occur
to match workload demand to ATP supply. This rate is regulated
in part by Ca2+-induced activation of several TCA enzymes; but
other factors are also involved (Vinnakota et al., 2011; Boelens
et al., 2013). On reperfusion, APoC was shown to depress mito-
chondrial respiration, to partially depolarize mitochondria, and
to decrease mitochondrial pH (Pravdic et al., 2010). These events
led to retarded mPTP opening and, consequently to better pre-
served m and ATP synthesis, and reduced intracellular and
mitochondrial Ca2+ overload and cell death (Pravdic et al., 2010).
Isoflurane pre- and post-conditioning was reported to induce
phosphorylation of mitochondrial proteins, with ANT phospho-
rylation as a novel mitochondrial therapeutic strategy for IR
injury that could confer protection by preventing the ischemic-
induced dephosphorylation of ANT (Feng et al., 2008). The
coordinated expression of two genomes, nuclear and mitochon-
drial, regulates the biogenesis of OxPhos (Garesse and Vallejo,
2001). One report suggested that sevoflurane induced delayed
conditioning by activating nuclear factor-κB (NF-κB) (Qiao et al.,
2013), an inducible transcription factor produced in response
to ROS and RNS, and that this modulation could help control
the transcription of DNA and cellular responses to stress stimuli
against myocardial injury by limiting apoptosis.
METABOLIC ROLE OF VA IN CARDIOPROTECTION
Mitochondria normally generate ATP by electron transport, H+
pumping and OxPhos. But during ischemia the shortage in sub-
strates and O2 decreases OxPhos promoting the working of F1F0
ATPase in reverse. Reduced cellular ATP levels stimulate glycol-
ysis causing lactic acidosis and a rise in intracellular Na+ by
activating the Na+-H+ exchanger (NHE). In turn this leads to
an increase in intracellular Ca2+ by activating the sarcolemmal
Na+-Ca2+ exchanger (NCE) (Murphy and Steenbergen, 2008a),
as shown in Figure 2. An alteration in mitochondrial membrane
transport protein function, e.g., VDAC, can contribute to IR
injury by impeding delivery of substrates required to carry out
OxPhos. In an overview of VDAC functional regulation in cell
death during cardiac IR, Das et al. (2012) suggested that less
entry of nucleotides via VDAC during IR injury might protect
cells by reducing the rate of ATP utilization. A decline in cell ATP
utilization during ischemia is considered fundamental for cardio-
protection in an IPC setting by improving ATP availability during
reperfusion (Murry et al., 1986). Thus, a decrease in ATP produc-
tion and reduced ATP entry into mitochondria through VDAC
could lead to reduced ATP consumption by F1F0-ATPase, and
to reduced glycolysis and lactic acidosis, which ultimately could
lead to decreased cytosolic Ca2+ loading via cation exchang-
ers (Murphy and Steenbergen, 2008a). A reduction in glycolysis
also leads to decreased cytosolic H+ and less H+ entry into
mitochondria.
The studies above indicate that alterations in mitochondrial
membrane proteins play crucial roles in indirectly modulating
mitochondrial Ca2+ overload and excess ROS emission. Indeed,
modulation of VDAC function by VA, directly or indirectly, as
reported by Jamnicki-Abegg et al. (2005), Raphael et al. (2006),
and Zhu et al. (2010), may reduce the vicious feed-forward
cycle of Ca2+ overload and ROS emission that culminates in
cell demise. Given the numerous roles of VDAC in transfer
of anion/cation and other metabolites, there could be addi-
tional mechanisms involving mitochondrial membrane proteins-
induced cardioprotection and any role of VA in these complex
mechanisms have yet to be explored.
EFFECTS OF VA ON SIGNAL TRANSDUCTION PATHWAYS
DURING IR INJURY
Exposure to VA preceding IR leads to activation of several sig-
naling cascades that involve protein kinases and “small” transient
ROS/RNS, including NO·. These signaling molecules eventually
converge on mitochondria to provide protection (Zaugg et al.,
2003b; Walters et al., 2012). Marinovic et al. (2006) provided evi-
dence in support of a dual role mKATP channels in VA protection,
i.e., as a trigger to initiate the signaling cascade and as an effector
responsible for the cardioprotective memory. APC with sevoflu-
rane was reported to improve vascular and mechanical function
by increasing NO· release that was blocked by an mKATP channel
inhibitor (Novalija et al., 1999). In an in vivo rat model, Ludwig
et al. (2004b) suggested that APC is mediated by opening of
mKATP channels and the subsequent generation of transient ROS,
which activates protein kinases. In another study, Pravdic et al.
(2009) inferred that APC is mediated by a PKC-δ-induced delay
of mPTP opening. Lastly, another study showed that APC pro-
tected the mouse heart against reperfusion injury by preventing
mPTP opening in an eNOS dependent manner, with NO• acting
as both the trigger and themediator of cardioprotection (Ge et al.,
2010).
The G protein coupled receptor 30 (GPR 30) agonist G1
improved cardiac function, reduced infarct size, and inhib-
ited mPTP opening by activating ERK signaling in the isolated
mouse hearts after IR (Bopassa et al., 2010). The pro-survival
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kinases ERK1/2 and PI3K/Akt also appear to contribute to VA
mediated cardioprotection (Raphael et al., 2005; Wang et al.,
2006b). Heat shock protein 90 (HSP 90), a cytoprotective pro-
tein, facilitated the translocation of PKC-ε after IR, and increased
phosphorylation of mitochondrial aldehyde dehydrogenase 2
(ALDH2) (Budas et al., 2010). ALDH2 is known to detoxify
4-hydroxynonenal (HNE), a cytotoxic end product of lipid per-
oxides following oxidative stress, by oxidizing the aldehyde group
(Camara et al., 2010). In this case, increased ALDH2 activity
resulted in reduced cardiac injury in an animal model of myocar-
dial infarction (Budas et al., 2010). A recent study showed that
isoflurane-induced APC alleviated hypoxia-reoxygenation injury
in conjunction with PKC-δ mediated activation of mitochon-
drial ALDH2 (Lang et al., 2013). Bouwman et al. (2006) reported
that activation of PKC-δ by sevoflurane increased sarcolemmal
NCE mediated myocardial Ca2+ influx, which may be a trigger of
cardioprotective signaling events during APC. Desflurane precon-
ditioning was reported to activate BKCa channels through protein
kinase A (PKA) (Redel et al., 2008). Exposure to isoflurane dur-
ing early reperfusion induced cardioprotection associated with
increased expression of the anti-apoptotic Bcl-2, a modulator
of mPTP (Wang et al., 2006a). Isoflurane also protected hearts
from IR injury, possibly by preventing excess ROS generation and
mPTP opening that in turn inhibited the activation of caspase-
3 (Wu et al., 2014). Although the signaling pathways are very
complex and incompletely resolved, it is likely that VA modulate
other known and unknown mitochondrial channel/transporters
involved in IR injury; but this remains to be tested.
OTHER POTENTIAL MITOCHONDRIAL TARGETS OF VA
DURING IR INJURY
POST-TRANSLATIONAL MODIFICATIONS
Beneficial post-translational modifications (PTMs) of mitochon-
drial proteins have been proposed to modulate cardioprotection
(Foster et al., 2009; Pagliaro et al., 2011; Porter et al., 2012). A
modification of mitochondrial protein by O-glycosylation with
O-linked-β-N-acetyl glucosamine (O-GlcNAc) was suggested to
occur with IPC as assessed by improved cardiac myocyte sur-
vival due to attenuated m (Jones et al., 2008). In a recent
study (Champattanachai et al., 2008) it was reported that the
protection by increased O-GlcNAc during injury of neonatal rat
ventricular myocytes was mediated by enhanced mitochondrial
Bcl-2 translocation. In vivo and ex vivo studies with isoflurane
preconditioning in mice demonstrated increased O-glycosylation
of cardiac mitochondrial VDAC associated with resistance to IR
stress (Hirose et al., 2011).
VA-mediated PTM (mostly phosphorylation) of mitochon-
drial proteins involved in bioenergetics and electron transport
complexes are implicated in the role of PTMs in regulating mito-
chondrial function that confers cardioprotection (Arrell et al.,
2006; Kalenka et al., 2006; Wong et al., 2010). However, addi-
tional studies are needed to validate the functional effects of
these changes during the various conditioning periods against
IR injury. Signaling RNS can also induce beneficial, reversible
PTMs. Specifically, S-nitrosylation of some mitochondrial pro-
teins may lead to cardioprotection during IPC and IPoC (Tullio
et al., 2013). As noted before, complex I dysfunction resulting
from oxidative damage is an important factor in the pathogenesis
of IR injury (Murray et al., 2003). Therefore, another possi-
ble mechanism of cardioprotection is modulation of complex I
protein by NO·-induced S-nitrosation leading to beneficial mod-
ulation of bioenergetics and redox signaling (Burwell et al., 2006).
Complex IV is another target of NO· where it competes with O2
at its binding site (Brookes et al., 2001); Similarly, VA were also
reported to modulate complex IV activity and to alter its func-
tion (Casanovas et al., 1983; Szabo and Zoratti, 1993); however,
whether this was through NO· was not evident. As noted earlier,
in our recent study (Agarwal et al., 2014), we did not observe an
effect of isoflurane on complex IV function. This discrepancy in
VA modulation of mitochondrial function as a cardioprotective
strategy further supports the complexity of VA interaction with
mitochondrial proteins.
Recently, changes in the mitochondrial proteome during
APC were assessed by a proteomic mass spectral approach
(Bienengraeber et al., 2013). An 18O-labeling method was applied
to relatively compare cardiac mitochondrial samples from con-
trol and isoflurane exposed rats before and after IR. It was found
that the activities of ATP synthase, a complex I subunit, cit-
rate synthase, and isocitrate dehydrogenase were increased after
APC compared to IR only based on phosphorylation of the
proteins (Bienengraeber et al., 2013). Since, those modulated
proteins directly belong to the OxPhos system, these observa-
tions further confirm the role of VA in altering mitochondrial
bioenergetics/metabolism.
MicroRNAs
miRNAs are endogenous, small non-coding, single stranded
RNAs (ssRNAs, ∼22 nucleotides) that are involved in transcrip-
tional and post-transcriptional regulation of gene expression
(Chen and Rajewsky, 2007). Several recent reports suggest miR-
NAs are novel therapeutic biomarkers for IR injury (Cheng et al.,
2010a), but their potential application in myocardial protection
against IR is not known. The up- or down-regulation of miRNAs
have been reported to occur during IR; in particular, protec-
tive effects of miRNAs with their target genes were identified
that reduced cardiac cell apoptosis during pre- and post- con-
ditioning against cardiac IR injury (Dong et al., 2009; Cheng
et al., 2010b; He et al., 2011). One study reported that upreg-
ulation of miRNAs was involved in delayed preconditioning, in
which miRNAs appeared to upregulate proteins (eNOS, HSP70)
involved in delayed preconditioning after IPC (Yin et al., 2009).
The role of miRNAs in APC or as a direct target of VA has not
been reported. However, according to a recent preliminary report
by Olson et al. (2013), in vitro application of isoflurane caused
upregulation of miR-21 and conferred cardioprotection, while
knockdown of miR-21 attenuated cardioprotection. Moreover, in
that study attenuation of APC during acute hyperglycemia was
also linked to regulation of miR-21; i.e., overexpression of miR-21
in cells exposed to high glucose restored APC via the Akt/GSK3β
link and increased cell survival.
MITOCHONDRIAL DNA
Mitochondria have their own genome that comprises only a small
portion of the total eukaryotic cell genome. The mitochondrial
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DNA (mDNA) encodes 13 mitochondrial proteins and the mito-
chondrial rRNAs and tRNAs needed for translation (Kirby and
Thorburn, 2008). Unlike the nuclear DNA, mDNA is not pro-
tected by histones and is therefore susceptible to damage by
oxidative stress (Camara et al., 2010). A decrease in mDNA is a
biological maker of myocardial damage, as in cardiac hypertro-
phy, that progresses to heart failure (Karamanlidis et al., 2011). A
recent study (Muravyeva et al., 2014) examined if mDNA mod-
ulates APC and cardiac susceptibility to IR injury by using two
strains of diabetic rats following exposure to isoflurane. The study
proposed that differences in the mitochondrial genome modu-
late isoflurane-induced generation of ROS that translates into
a differential susceptibility to APC; this suggested a potentially
important role of mDNA in regulating cardioprotection in APC
via modulation of ROS production.
CONCLUSIONS AND FUTURE DIRECTIONS
Improvement in the clinical management of ischemic heart dis-
ease remains elusive despite the discovery of many molecular
and cellular mechanisms that may be valuable targets to treat
against IR injury. The importance of mitochondrial bioener-
getics and function in contributing not only to cardiac injury
but also to reducing cardiac injury is now well recognized. But
there remains a lack of clear understanding of the mitochondrial-
cytosolic mechanisms that might lead to more targeted interven-
tion. Hence, we need to identify new targets that could uncover
the mechanisms of dysfunction associated with IR injury. With
a better understanding of mitochondrial targets as hubs for
controlling metabolism and cellular redox signaling pathways
that elicit protection, we could better develop novel therapeutic
drugs for clinical trials to protect against IR injury. Because VA
are lipophilic agents with multi-targeted actions that, together,
confer cardioprotection, they give us valuable clues into which
potential sites to investigate; these clues may be especially use-
ful to selectively and reversibly target mitochondria to reduce
IR injury. Unfortunately, as summarized in this review, there
is contradictory evidence with respect to the potentially large
number of pathways by which VA might protect the heart.
Nonetheless, there are molecules with characteristics of a VA
but without anesthetic properties. These could be developed as
cardioprotective drugs while obviating the need for inducing
anesthesia.
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